Tigecycline: An antibiotic for the twenty-first century

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue SUPPL.2, 2013, Pages

  Dryden, Matthew ^a  

^a BASINGSTOKE AND NORTH HAMPSHIRE HOSPITAL   (United Kingdom)

Author keywords

Anti Infective development; Antibiotics; Tetracyclines

Indexed keywords

GLYCYLCYCLINE DERIVATIVE; OXAZOLIDINONE DERIVATIVE; POLYPEPTIDE ANTIBIOTIC AGENT; TIGECYCLINE;

ABDOMINAL INFECTION; ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL PRACTICE; ENTEROBACTERIACEAE; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; HUMAN; INFECTION COMPLICATION; INFECTION CONTROL; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MONOTHERAPY; OPPORTUNISTIC INFECTION; PRESCRIPTION; RISK BENEFIT ANALYSIS; SANITATION; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS AUREUS;

ANTI-INFECTIVE DEVELOPMENT; ANTIBIOTICS; TETRACYCLINES;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DRUG THERAPY, COMBINATION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EUROPE; HUMANS; INTRAABDOMINAL INFECTIONS; MINOCYCLINE; SKIN DISEASES, BACTERIAL; SOFT TISSUE INFECTIONS; TREATMENT OUTCOME;

EID: 84879336181     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt139     Document Type: Article

References (13)

1. Wise R. The urgent need for new antibacterial agents. J Antimicrob Chemother 2011; 66: 1939-40.
2. Livermore DM. Discovery research: the scientific challenge of finding new antibiotics. J Antimicrob Chemother 2011; 66: 1941-4.
3. Kasbekar N. Tigecycline: a new glycylcycline antimicrobial agent. Am J Health Syst Pharm 2006; 63: 1235-43.
4. Rose WE, Rybak MJ. Tigecycline: first of a new class of antimicrobial agents. Pharmacotherapy 2006; 26: 1099-110.
5. Kumarasamy KK, Toleman MA, Walsh TR et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis 2010; 10: 597-602.
6. Bassetti M, Eckmann C, Bodmann KF et al. Prescription behaviours for tigecycline in real-life clinical practice from five European observational studies. J Antimicrob Chemother 2013; 68 Suppl 2: ii5-14.
7. Heizmann WR, Dupont H, Montravers P et al. Resistance mechanisms and epidemiology of multiresistant pathogens in Europe and efficacy of tigecycline in observational studies. J Antimicrob Chemother 2013; 68 Suppl 2: ii45-55.
8. Montravers P, Bassetti M, Dupont H et al. Efficacy of tigecycline for the treatment of complicated skin and soft-tissue infections in real-life clinical practice from five European observational studies. J Antimicrob Chemother 2013; 68 Suppl 2: ii15-24.
9. Eckmann C, Montravers P, Bassetti M et al. Efficacy of tigecycline for the treatment of complicated intra-abdominal infections in real-life clinical practice from five European observational studies. J Antimicrob Chemother 2013; 68 Suppl 2: ii25-35.
10. Guirao X, Sánchez Garciá M, Bassetti M et al. Safety and tolerability of tigecycline for the treatment of complicated skin and soft-tissue and intra-abdominal infections: an analysis based on five European observational studies. J Antimicrob Chemother 2013; 68 Suppl 2: ii37-44.
11. European Medicines Agency. Questions and Answers on the Review of Tygacil (Tigecycline): Outcome of a Renewal Procedure (17 February 2011). http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/human/000644/WC500102228.pdf (22 March 2012, date last accessed).
12. US FDA. FDA Drug Safety Communication: Increased Risk of Death With Tygacil (Tigecycline) Compared to Other Antibiotics Used to Treat Similar Infections (1 September 2010). http://www.fda.gov/drugs/drugsafety/ucm224370.htm (26 September 2012, date last accessed).
13. European Medicines Agency. EPAR Summary for the Public: Tygacil (last updated February 2012). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000644/WC500044509.pdf (6 November 2012, date last accessed).